Delivery Order SPE2DB20D3303-SPE2DB25FA4GB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Fulphila 6 mg/0.6 ml syringes valued at $6,205.73, with completion expected by July 31, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery under AmerisourceBergen's larger federal...
- The Defense Logistics Agency awarded a delivery order valued at $5,314.82 to AmerisourceBergen Drug Corp for Fulphila 6 mg/0.6 mL syringes on September 4, 2025, with completion scheduled for September 5, 2025. This delivery order operates under a firm fixed price structure with no set-aside designation, indicating open competitive award. The pharmaceutical product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $6,978.73 to AmerisourceBergen Drug Corp for Fulphila 6 mg/0.6 mL syringes with an ultimate completion date of September 22, 2025. The contract employs firm fixed price pricing and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for the supply of Fulphila 6 mg/0.6 mL syringes. The contract has a ceiling value of $14,031.60 and a firm fixed price structure with an ultimate completion date of July 1, 2025. This award was not designated as a set-aside contract and represents a competitively awarded delivery order. The place of performance is AmerisourceBergen's corporate office location in...
- AmerisourceBergen Drug Corp was awarded a delivery order on July 22, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply FULPHILA 6 mg/0.6 mL syringes with a contract value of $10,523.70. The delivery order is structured as a firm fixed price contract with no set-aside designation, indicating it was competitively awarded. Performance of this delivery order will be completed by July 23, 2025, at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Fulphila 6 mg/0.6 mL syringes with a ceiling value of $2,834.88. This is a firm fixed-price delivery order with an ultimate completion date of May 5, 2025, to be performed at the vendor's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the vendor's capability to meet federal procurement requirements...
- This delivery order, awarded on September 23, 2025, represents a $15,949.72 firm fixed-price purchase of Fulphila 6 mg/0.6 mL syringes from AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract is funded by the Defense Logistics Agency's Medical Supply Chain and has a completion date of September 24, 2025. This award was not set aside and was competitively awarded, reflecting the vendor's established capability to meet federal...
- This is a $26,744.35 Firm Fixed Price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The award is for the supply of FULPHILA 6 MG/0.6 ML SYRINGE 0.6ML, a medical product used in healthcare. The contract has an ultimate completion date of December 27, 2024. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is the prime contractor and there are no reported subcontractors. This delivery order is part of a larger Indefinite Delivery...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Fulphila 6 mg/0.6 ml syringes. The contract has a firm fixed price of $1,006.88 and a completion date of June 5, 2025. This contract is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00, which...
- This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Fulphila 6 mg/0.6 mL syringes. The $11,674.80 firm fixed-price delivery order has a completion date of November 5, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a range of pharmaceutical products and medical supplies to...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA4GBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,787.50 to AmerisourceBergen Drug Corp for the supply of Fulphila 6 mg/0.6 mL syringes on September 26, 2025, with an ultimate completion date of September 29, 2025. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government. The product will be delivered to the company's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters as a major pharmaceutical distributor supporting federal medical procurement. This delivery order operates under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a vast range of pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide, including customers such as the Defense Health Agency and the U.S. Coast Guard. The delivery of Fulphila, a biologic medication used for chemotherapy side effect management, demonstrates the contractor's role in providing specialized pharmaceutical commodities essential to federal health service operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 9/26/25 |